On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors

Cancer Discov. 2022 May 2;12(5):1179. doi: 10.1158/2159-8290.CD-RW2022-041.

Abstract

Resistance to noncovalent BTK inhibitors is mediated by non-C481 BTK and PLCγ2 mutations.

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase* / genetics
  • Humans
  • Mutation

Substances

  • Agammaglobulinaemia Tyrosine Kinase